argenx SE (ARGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

argenx SE (ARGX) closed at USD 818.30 on 2026-10-14, a change of -2.2 % over the past year, with a market capitalization of USD 53.22B.

argenx SE recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

argenx SE key figures

Previous close

USD 818.30 (2026-10-14)

1-year change

-2.2 %

Market cap

USD 53.22B

Enterprise value

USD 1.32T

P/E ratio (trailing)

30.57

P/E ratio (forward)

23.78

EPS (trailing)

27.68

EPS (forward)

35.59

PEG ratio

1.01

Price to book

157.19

Revenue growth

59.3 %

Earnings growth

95.2 %

Dividend per share (trailing)

0.00

Short ratio

5.51

Employees

1,863

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for argenx SE and compare it with other stocks.